EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ALGS: Aligos Therapeutics Inc

15 Oct 25 17:07
LAST:

10.38

CHANGE:
 0.72		OPEN:
9.61		HIGH:
10.44		ASK:
0.00		VOLUME:
135.9K
CHG(%):
7.45		PREV:
9.66		LOW:
9.45		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
15 Oct 259.6110.449.4510.38135.9K
14 Oct 259.189.669.029.66116.2K
13 Oct 259.449.789.089.47179.9K
10 Oct 2510.2710.319.289.43115.1K
09 Oct 259.9010.369.7910.21143.2K
08 Oct 259.9710.059.619.9362.5K
07 Oct 2510.4010.659.669.84103.8K
06 Oct 2510.1110.319.8910.2254.5K
03 Oct 2510.1810.189.6010.0786.9K
02 Oct 2510.3210.7010.1110.2440.6K

COMPANY PROFILE

Name:Aligos Therapeutics Inc
About:Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:One Corporate Drive, South San Francisco, CA, United States, 94080
Website:https://www.aligos.com
CUSIP:01626L105
CIK:0001799448
ISIN:US01626L2043
FIGI:BBG00QX7QH68

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:9.835.6%
MA10:9.954.4%
MA20:9.934.6%
MA50:9.726.8%
MA100:8.7019.3%
MA200:12.1717.3%
STO9:77.87
STO14:74.80
RSI14:62.38 
MTM14:0.59
ROC14:0.06 
ATR:0.73 
Week High:10.440.5%
Week Low:9.0215.1%
Month High:11.399.7%
Month Low:8.9017.3%
Year High:46.80350.9%
Year Low:3.76176.1%
Volatility:58.97 

RECENT SPLITS

Date Ratio
19 Aug 20241-25